TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D and TG-N for the regeneration of cartilage, bone, disc and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
TissueGene’s mission is to provide safe and effective therapies to the healthcare industry by reducing the pain and suffering associated with various orthopedic diseases and degenerative disorders. We believe the key to permanent recovery lies within the complexities of self-regeneration and have focused on harnessing these biological processes to improve the quality of life for patients worldwide.